Foundayo Pill Side Effects: UK Safety Guide

Foundayo pill side effects are a common search query, but Foundayo does not correspond to any medicine holding a marketing authorisation from the MHRA, nor does it appear in the NHS medicines compendium or NICE database as a licensed product. It may be a herbal supplement, an unlicensed product sold online, or a brand used in another country without UK regulatory approval. Because no verified Summary of Product Characteristics or Patient Information Leaflet exists for a UK-authorised Foundayo medicine, confirmed side effects cannot be listed. This article explains what that means for your safety and what to do instead.

What is the Foundayo pill and how does it work?

Foundayo is not an MHRA-authorised medicine and has no verified mechanism of action, SmPC, or PIL in the UK. It may be an unlicensed supplement or overseas brand not approved for UK use.

A product called Foundayo could not be confirmed in the MHRA's register of authorised medicines, the NICE technology appraisal database, or the NHS medicines compendium through the sources available to us when this article was prepared. Regulatory approvals can be granted at any time, so you should verify the current status of any medicine directly at products.mhra.gov.uk before purchasing or taking it.

Foundayo has been described in some sources as a brand name for orforglipron, an oral non-peptide GLP-1 receptor agonist in clinical development for weight management and type 2 diabetes. We were unable to confirm a published UK Summary of Product Characteristics (SmPC) or Patient Information Leaflet (PIL) for a product called Foundayo through the authoritative sources available to us. If orforglipron has since received a UK marketing authorisation under this or any other brand name, the mechanism of action, licensed indications, and safety profile will be set out in the SmPC and PIL, which can be searched at medicines.org.uk/emc and products.mhra.gov.uk.

If you have seen Foundayo described as a licensed medicine, please verify this directly with the MHRA's product search at products.mhra.gov.uk before purchasing or taking it. If you have encountered Foundayo through an online retailer, social media, or an unregulated website and cannot confirm its regulatory status, it is important to exercise caution. Products sold without a UK marketing authorisation may contain undisclosed ingredients, inaccurate labelling, or substances that interact with other medicines. Before taking any product whose regulatory status is unclear, speak to your GP or a registered pharmacist, who can help you assess whether it is appropriate and safe for you.

What side effects can the Foundayo pill cause?

No verified side-effect profile can be provided as Foundayo lacks an MHRA marketing authorisation. If you experience symptoms after taking it, stop use and contact your GP or report via the MHRA Yellow Card scheme.

Because a verified UK SmPC or PIL for Foundayo could not be confirmed through the authoritative sources available to us, it is not possible to provide a clinically reviewed, product-specific list of side effects in this article. Providing a side-effect profile without a verified source would risk misleading readers.

If Foundayo is confirmed as a licensed medicine (for example, as a brand of orforglipron), the full list of side effects will be set out in the PIL, which will be available at medicines.org.uk/emc. You should read the PIL before starting any new medicine and discuss any concerns with your prescriber or pharmacist.

If you are experiencing symptoms that you believe may be related to taking Foundayo or any other product, contact your prescriber or pharmacist promptly. If you suspect a serious reaction, stop taking the product and seek urgent medical advice. Suspected adverse reactions to any product, including unlicensed supplements, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting system helps the MHRA monitor the safety of products available in the UK, and your report can contribute to protecting other people who may be using the same product.

Are there any serious risks I should watch out for?

The main risk is the absence of independent safety data, meaning serious harms may go undetected. Seek urgent medical advice if you develop jaundice, palpitations, severe abdominal pain, or signs of allergic reaction.

The most significant risk associated with any product whose regulatory status cannot be confirmed is the absence of independent safety data, which means serious harms may not be identified until after widespread use. Without an MHRA-authorised SmPC, there is no formal guidance on contraindications, drug interactions, or warning signs that should prompt medical attention. This is a meaningful patient safety concern, particularly for people who have existing health conditions or who take prescribed medicines.

The MHRA has previously found that unlicensed products sold online, particularly those marketed for weight loss, can contain undisclosed pharmaceutical ingredients, including prescription-only medicines or controlled substances, at doses not declared on the label.

If you develop any of the following after taking a product whose composition or regulatory status is uncertain, seek prompt medical advice from your GP or contact NHS 111:

• Severe or persistent abdominal pain

• Unexplained changes in heart rate or palpitations

• Jaundice (yellowing of the skin or eyes), which may indicate liver involvement

• Severe allergic reactions, including rash, swelling of the face or throat, or difficulty breathing (call 999 immediately if breathing is affected)

• Significant changes in mood, behaviour, or mental health

If Foundayo is confirmed as a licensed medicine, the SmPC and PIL will set out the specific serious risks, contraindications, and warning signs relevant to that product. You should read these documents and follow the guidance of your prescriber. If you are pregnant, breastfeeding, or planning a pregnancy, do not take any product whose safety in these groups has not been established without explicit medical advice.

Who should avoid taking Foundayo?

Pregnant or breastfeeding women, people with chronic health conditions, those on prescribed medicines, children, and older adults should all avoid unlicensed products and seek medical advice before use.

Because a verifiable MHRA-authorised product licence for Foundayo could not be confirmed through the sources available to us, it is not possible to provide a clinically verified list of contraindications or populations who should specifically avoid it. If Foundayo is confirmed as a licensed medicine, the contraindications and cautions will be set out in the SmPC (sections 4.3 and 4.4) and PIL, available at medicines.org.uk/emc.

General principles of medicine safety apply to any product whose composition and regulatory status are uncertain. People in the following groups should be especially cautious about taking any product that has not been verified as licensed and should seek medical advice before doing so:

• Pregnant or breastfeeding women: The safety of unverified products in pregnancy and lactation is almost never established, and some ingredients may be harmful to a developing baby or infant.

• People with chronic health conditions: Those with liver disease, kidney disease, cardiovascular conditions, diabetes, or thyroid disorders may be at greater risk of harm from unverified ingredients.

• People taking prescribed medicines: The risk of interactions between unverified products and prescription medicines is real and may not be predictable without knowing the full ingredient list.

• Children and adolescents: Products not specifically licensed for use in younger age groups should not be given to children or teenagers without medical supervision.

• Older adults: Age-related changes in metabolism and organ function can alter how the body processes substances, increasing the risk of adverse effects.

If you are unsure whether a product is appropriate for you, your GP or a registered pharmacist is the right first point of contact. In Great Britain, pharmacists are registered with the General Pharmaceutical Council (GPhC); in Northern Ireland, the regulator is the Pharmaceutical Society of Northern Ireland (PSNI). A registered pharmacist can check for known interactions and advise on whether a product is likely to be safe given your individual circumstances.

How does Foundayo compare to other options available in the UK?

Foundayo cannot be meaningfully compared to licensed medicines as it holds no UK authorisation. MHRA-approved weight-management options include semaglutide, tirzepatide, liraglutide, and orlistat, all with documented safety profiles.

Because the UK marketing authorisation status of Foundayo could not be confirmed through the authoritative sources available to us, a direct comparison with other licensed medicines cannot be made on the basis of verified clinical data. If Foundayo is confirmed as a licensed medicine (for example, as a brand of orforglipron), its efficacy and safety profile will be set out in the SmPC and any relevant NICE technology appraisal, which can be searched at nice.org.uk and medicines.org.uk/emc.

Several medicines are currently licensed in the UK for chronic weight management and have been evaluated through rigorous clinical programmes before receiving regulatory approval. These include semaglutide (Wegovy, available as a subcutaneous injection and as an oral tablet formulation authorised by the MHRA in June 2026), liraglutide (Saxenda), tirzepatide (Mounjaro), and orlistat (available in both prescription and lower-dose over-the-counter forms). Semaglutide and liraglutide are GLP-1 receptor agonists that work by mimicking gut hormones to regulate appetite and blood glucose.^[16] Tirzepatide is a dual GIP and GLP-1 receptor agonist with a related but distinct mechanism. The benefits and risks of these medicines are documented in published SmPCs and NICE guidance. Local Integrated Care Boards (ICBs) make commissioning decisions about NHS access, and availability on the NHS is not automatic following a NICE recommendation and varies by ICB.^[17]

For people considering a licensed weight-management medicine through a private route, it is important to choose a regulated provider. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a licensed medicine may be one option a prescriber considers if it is clinically appropriate. When evaluating any provider, check that the pharmacy is registered with the GPhC (for pharmacies in Great Britain) or the PSNI (for pharmacies in Northern Ireland), and that prescribers are registered with the General Medical Council at gmc-uk.org. Choosing a licensed medicine through a regulated pathway offers meaningful protections that unverified products cannot provide.

Frequently Asked Questions